Soligenix, Inc. Common Stock
SNGXStock
$0.36−70.24%52W
Market Cap$5.53M
P/E—
Div yield—
Beta2.01
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-83.98%
Price vs S&P 500 (4W)-13.15%
VGM Score29.59
Market Capitalization$5.53M
Earnings Surprise History
Q1 26-0.28est. -0.29
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SNGXSoligenix, Inc. Common Stock | B | F | F | $0.36 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Soligenix is a biopharmaceutical company developing therapeutics and vaccines for rare diseases and public health threats with unmet medical needs. Operating through Specialized BioTherapeutics and Public Health Solutions segments, the company generates primary revenues from Public Health Solutions, including RiVax (a ricin toxin vaccine candidate), SGX943 (for antibiotic-resistant and emerging infectious diseases), and vaccine research programs targeting Ebola, Marburg, and SARS-CoV-2.